Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer

- Moran-Jones, Kim, Gloss, Brian S., Spong, Suzanne M., Scarlett, Christopher J., Hacker, Neville F., Ghosh, Sue, Mok, Samuel C., Birrer, Michael J., Samimi, Goli, Murali, Rajmohan, Chang, David K., Colvin, Emily K., Jones, Marc D., Yuen, Samuel, Howell, Viive M., Brown, Laura M., Wong, Carol W.

Optimal uptake rates for initial treatments for cervical cancer in concordance with guidelines in Australia and Canada: results from two large cancer facilities

- Kang, Yoon-Jung, O'Connell, Dianne L., Barton, Michael, Canfell, Karen, Tan, Jeffrey, Lew, Jie-Bin, Demers, Alain, Lotocki, Robert, Kliewer, Erich V., Hacker, Neville F., Jackson, Michael, Delaney, Geoff P.

A clinicopathological review of 33 patients with vulvar melanoma identifies c-KIT as a prognostic marker

- Heinzelmann-Schwarz, Viola A., Nixdorf, Sheri, Valadan, Mehrnaz, Diczbalis, Monica, Olivier, Jake, Otton, Geoff, Fedier, André, Hacker, Neville F., Scurry, James P.

Loss of secreted frizzled-related protein 4 correlates with an aggressive phenotype and predicts poor outcome in ovarian cancer patients

- Jacob, Francis, Ukegjini, Kristjan, Fink, Daniel A., Hacker, Neville F., Heinzelmann-Schwarz, Viola A., Nixdorf, Sheri, Ford, Caroline E., Olivier, Jake, Caduff, Rosmarie, Scurry, James P., Guertler, Rea, Hornung, Daniela, Mueller, Renato